51 recruiting, 19 terminated, 18 active not recruiting, 15 completed. 100 Phase 1, 39 Phase 2, 7 Not applicable, 1 Early Phase 1.
Follow Metastatic Solid Tumor: new trials by email Literature Review of Metastatic Solid Tumor trials Research Report on Metastatic Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors ISM5939, Cisplatin, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | InSilico Medicine Hong Kong Limited | 159 | 2026-12-30 | 2026-07-23 |
| Adding Spatially Fractionated Radiation Therapy to Standard Palliative Radiation for Improving Disease-Related Symptoms in Patients With Unresectable Solid Tumors Electronic Health Record Review, External Beam Radiation Therapy, Questionnaire Administration - Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Not applicable | Recruiting | Mayo Clinic | 100 | 2026-09-23 | 2026-10-07 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil Solid Tumor, Metastatic Solid Tumor | Not yet recruiting | Latin American Cooperative Oncology Group | 250 | 2026-09-01 | 2026-08-26 | |
| First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors DS1025a - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Daiichi Sankyo | 45 | 2026-08-06 | 2026-10-23 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors IDP-001 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | InduPro, Inc. | 132 | 2026-07-08 | 2026-09-03 |
| A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors ZE94-0605 - Advanced Solid Tumor Cancer, Metastatic Solid Tumor | Phase 1 | Recruiting | Eilean Therapeutics | 60 | 2026-06-25 | 2026-07-29 |
| FORTRAS: A Study of MSK-TCR5 in People With Solid Tumor Cancers MSK-TCR5 - Solid Tumor, Solid Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2026-06-09 | 2026-06-15 |
| Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers Prophylactic External Beam Radiotherapy, Standard of Care - Bone Metastases, Metastatic Solid Tumor | Phase 2 | Recruiting | Institute of Oncology Ljubljana | 90 | 2026-06-02 | 2026-10-09 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies IPN01203 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ipsen | 102 | 2026-02-06 | 2026-09-03 |
| A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy ITC-6146RO - Metastatic Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer | Phase 1 | Not yet recruiting | IntoCell, Inc | 102 | 2026-02-06 | 2026-02-20 |
| Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors BSI-082, Trastuzumab deruxtecan - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | Lei Zheng | 57 | 2026-01-26 | 2026-10-15 |
| A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours IPN60300 - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 / Phase 2 | Recruiting | Ipsen | 114 | 2025-12-05 | 2026-10-01 |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors PLX-61639 - Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Plexium, Inc. | 155 | 2025-12-01 | 2026-06-12 |
| Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies MPT0B640 - Advanced Solid Tumor, Metastatic Solid Tumor | Early Phase 1 | Withdrawn | J Ints Bio | 2025-12-01 | 2024-03-06 | |
| Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors SYN818 and Olaparib will be administered - Metastatic Solid Tumor, Ovarian Cancer | Phase 1 | Recruiting | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 110 | 2025-08-26 | 2025-09-05 |
| Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors SYN608 - Advanced Solid Cancer, Metastatic Solid Tumor | Phase 1 | Not yet recruiting | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd | 105 | 2025-07-31 | 2025-07-28 |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors MOMA-341, Irinotecan, Immunotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | MOMA Therapeutics | 132 | 2025-07-16 | 2026-07-23 |
| Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors YH32364 - EGFR Overexpression, Locally Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Yuhan Corporation | 80 | 2025-06-12 | 2026-06-10 |
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT3789, pembrolizumab - Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Terminated | Prelude Therapeutics Incorporated | 6 | 2025-06-03 | 2026-02-02 |
Showing 20 of 125. Sign in to see all of them.
Neoplasm Metastasis (125) · Carcinoma, Non-Small-Cell Lung (26) · Neoplasms (13) · Colorectal Neoplasms (12) · Breast Neoplasms (11) · Lung Neoplasms (11) · Pancreatic Neoplasms (11) · Ovarian Neoplasms (10) · Carcinoma, Renal Cell (9) · Prostatic Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (7) · Melanoma (6) · Triple Negative Breast Neoplasms (6) · Cholangiocarcinoma (5) · Esophageal Neoplasms (5)
Neoplastic Processes (125) · Pathologic Processes (125) · Pathological Conditions, Signs and Symptoms (125) · Neoplasms (112) · Neoplasms by Site (50) · Neoplasms by Histologic Type (33) · Lung Diseases (31) · Respiratory Tract Diseases (31) · Respiratory Tract Neoplasms (31) · Thoracic Neoplasms (31) · Bronchial Neoplasms (27) · Carcinoma (27) · Carcinoma, Bronchogenic (27) · Neoplasms, Glandular and Epithelial (27) · Digestive System Diseases (25)
pembrolizumab (16) · Cisplatin (4) · Docetaxel (4) · Irinotecan (4) · repotrectinib (4) · tislelizumab (4) · Carboplatin (3) · Cetuximab (3) · Drug Therapy (3) · Immunotherapy (3) · Nivolumab (3) · cemiplimab (3) · olaparib (3) · Ado-Trastuzumab Emtansine (2) · Fluorouracil (2)
Memorial Sloan Kettering Cancer Center (5) · Turning Point Therapeutics, Inc. (5) · Eli Lilly and Company (4) · BeOne Medicines (3) · Daiichi Sankyo (3) · GI Innovation, Inc. (3) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd (3) · Jazz Pharmaceuticals (3) · Nuvalent Inc. (3) · Prelude Therapeutics Incorporated (3) · Ascendis Pharma Oncology Division A/S (2) · BeiGene (2) · Exelixis (2) · Ipsen (2) · MOMA Therapeutics (2)
United States (86) · Spain (25) · Australia (24) · South Korea (23) · France (18) · China (14) · Canada (12) · Japan (11) · Italy (10) · Taiwan (10) · Belgium (9) · Germany (8) · Netherlands (8) · United Kingdom (8) · Singapore (6)
Nari Yun, PhD (2) · Abdul Naqash, MD (1) · Adam Schoenfeld, MD (1) · Atif Khan, MD (1) · Aung Naing, MD, FCAP (1) · Cesar Santa-Maria, MD (1) · Chaoyuan Kuang, MD, PhD (1) · Christopher Nevala-Plagemann, MD (1)
PMID 33859942, PMID 35817480, PMID 36123697, PMID 37279836, PMID 38485184, PMID 39574115, PMID 40250867, PMID 40543428, PMID 40635151, PMID 40932470, PMID 41022754, PMID 41423415, PMID 41428976, PMID 41740031, PMID 42351304, PMID 42410111, PMID 42440368, PMID 42581203, PMID 42753220
2023 (4), 2019 (3), 2025 (2)